Clinical Trial Update: Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating afatinib as second-line therapy for non-small cell lung cancer with EGFR mutation; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 4 | Status: COMPLETED | Results posted: 2018-12-17